EURURO Vol. 72 No. 4

[20] Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human

breast tumours. Nature 2000;406:747–52.

[21] Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL.

Gene expression profiling predicts clinical outcome of prostate

cancer. J Clin Invest 2004;113:913–23.

[22] Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic

profiling of human prostate cancer. Cancer Cell 2010;18:11–22.

[23] Tibshirani R, Walther G, Hastie T. Estimating the number of clusters

in a data set via the gap statistic. J R Stat Soc Ser B (Stat Methodol)

2001;63:411–23.

[24] Grambsch PM, Therneau TM. Proportional hazards tests and diag-

nostics based on weighted residuals. Biometrika 1994;81:515–26.

[25] Kypta RM, Waxman J. Wnt/beta-catenin signalling in prostate

cancer. Nat Rev Urol 2012;9:418–28.

[26] Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list

enrichment analysis and candidate gene prioritization. Nucl Acids

Res 2009;37(Web Server issue):W305–11.

[27] Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh

PC. Natural history of progression after PSA elevation following

radical prostatectomy. JAMA 1999;281:1591–7.

[28] Li H, Liu W, Chen W, Zhu J, Deng CX, Rodgers GP. Olfactomedin

4 deficiency promotes prostate neoplastic progression and is asso-

ciated with upregulation of the hedgehog-signaling pathway. Sci

Rep 2015;5:16974.

[29]

[30] Aytes A, Mitrofanova A, Lefebvre C, et al. Cross-species regulatory

network analysis identifies a synergistic interaction between

FOXM1 and CENPF that drives prostate cancer malignancy. Cancer

Cell 2014;25:638–51.

E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 0 9 – 5 1 8

518